Last reviewed · How we verify
Fibrovein
At a glance
| Generic name | Fibrovein |
|---|---|
| Also known as | Fibrovein S.T.D pharmaceutical products LTD |
| Sponsor | Oslo University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Compare Two Different Sclerosing Agents in the Treatment of Venous Malformations (PHASE4)
- Laser Ablation Versus Mechanochemical Ablation Trial (PHASE4)
- RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fibrovein CI brief — competitive landscape report
- Fibrovein updates RSS · CI watch RSS
- Oslo University Hospital portfolio CI